Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 163

1.

Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience.

Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N.

Circulation. 2007 Mar 13;115(10):1234-43. Epub 2007 Feb 19.

2.

Effect of hypoxia-inducible factor-1alpha gene therapy on walking performance in patients with intermittent claudication.

Creager MA, Olin JW, Belch JJ, Moneta GL, Henry TD, Rajagopalan S, Annex BH, Hiatt WR.

Circulation. 2011 Oct 18;124(16):1765-73. doi: 10.1161/CIRCULATIONAHA.110.009407. Epub 2011 Sep 26.

3.

Results of a double-blind, placebo-controlled study to assess the safety of intramuscular injection of hepatocyte growth factor plasmid to improve limb perfusion in patients with critical limb ischemia.

Powell RJ, Simons M, Mendelsohn FO, Daniel G, Henry TD, Koga M, Morishita R, Annex BH.

Circulation. 2008 Jul 1;118(1):58-65. doi: 10.1161/CIRCULATIONAHA.107.727347. Epub 2008 Jun 16.

4.

Regional angiogenesis with vascular endothelial growth factor in peripheral arterial disease: a phase II randomized, double-blind, controlled study of adenoviral delivery of vascular endothelial growth factor 121 in patients with disabling intermittent claudication.

Rajagopalan S, Mohler ER 3rd, Lederman RJ, Mendelsohn FO, Saucedo JF, Goldman CK, Blebea J, Macko J, Kessler PD, Rasmussen HS, Annex BH.

Circulation. 2003 Oct 21;108(16):1933-8. Epub 2003 Sep 22.

5.

Expression of constitutively stable hybrid hypoxia-inducible factor-1alpha protects cultured rat cardiomyocytes against simulated ischemia-reperfusion injury.

Date T, Mochizuki S, Belanger AJ, Yamakawa M, Luo Z, Vincent KA, Cheng SH, Gregory RJ, Jiang C.

Am J Physiol Cell Physiol. 2005 Feb;288(2):C314-20. Epub 2004 Oct 20.

PMID:
15496478
6.

A hypoxic inducible factor-1 alpha hybrid enhances collateral development and reduces vascular leakage in diabetic rats.

Kajiwara H, Luo Z, Belanger AJ, Urabe A, Vincent KA, Akita GY, Cheng SH, Mochizuki S, Gregory RJ, Jiang C.

J Gene Med. 2009 May;11(5):390-400. doi: 10.1002/jgm.1318.

PMID:
19291676
7.

A constitutively active hypoxia-inducible factor-1alpha/VP16 hybrid factor activates expression of the human B-type natriuretic peptide gene.

Luo Y, Jiang C, Belanger AJ, Akita GY, Wadsworth SC, Gregory RJ, Vincent KA.

Mol Pharmacol. 2006 Jun;69(6):1953-62. Epub 2006 Feb 28.

8.
9.

The efficacy of a 'master switch gene' HIF-1alpha in a porcine model of chronic myocardial ischaemia.

Heinl-Green A, Radke PW, Munkonge FM, Frass O, Zhu J, Vincent K, Geddes DM, Alton EW.

Eur Heart J. 2005 Jul;26(13):1327-32. Epub 2005 Apr 8.

PMID:
15821009
10.

[Construction and identification of adenovirus vector for double-mutant human hypoxia-inducible factor-1alpha gene].

Tong K, Xie YJ, Wang YG, Guo SG, Lai WY, Wu PS.

Nan Fang Yi Ke Da Xue Xue Bao. 2007 Apr;27(4):445-7. Chinese.

11.

[Therapeutic effect of hypoxia-inducible factor-1alpha on focal cerebral ischemia: experiment with rats].

Tan XJ, Hu CL.

Zhonghua Yi Xue Za Zhi. 2006 Apr 18;86(15):1057-60. Chinese.

PMID:
16784711
12.

Gene therapy progress and prospects: therapeutic angiogenesis for limb and myocardial ischemia.

Khan TA, Sellke FW, Laham RJ.

Gene Ther. 2003 Feb;10(4):285-91. Review.

PMID:
12595887
13.

Angiogenic Gene Therapy (AGENT) trial in patients with stable angina pectoris.

Grines CL, Watkins MW, Helmer G, Penny W, Brinker J, Marmur JD, West A, Rade JJ, Marrott P, Hammond HK, Engler RL.

Circulation. 2002 Mar 19;105(11):1291-7.

14.

Expression of hypoxia-inducible factor 1alpha gene affects the outcome in patients with ovarian cancer.

Shimogai R, Kigawa J, Itamochi H, Iba T, Kanamori Y, Oishi T, Shimada M, Sato S, Kawaguchi W, Sato S, Terakawa N.

Int J Gynecol Cancer. 2008 May-Jun;18(3):499-505. doi: 10.1111/j.1525-1438.2007.01055.x.

PMID:
18476949
15.

Regulation of vascularization by hypoxia-inducible factor 1.

Semenza GL.

Ann N Y Acad Sci. 2009 Oct;1177:2-8. doi: 10.1111/j.1749-6632.2009.05032.x.

PMID:
19845601
16.

Construction of recombinant adenoviral vector overexpressing human HIF-1alpha gene.

Yu RT, Zhu YF, Tang H.

Sheng Wu Gong Cheng Xue Bao. 2003 Jan;19(1):107-11.

PMID:
15969046
17.

In vivo enhancement of angiogenesis by adenoviral transfer of HIF-1alpha-modified endothelial progenitor cells (Ad-HIF-1alpha-modified EPC for angiogenesis).

Jiang M, Wang B, Wang C, He B, Fan H, Shao Q, Gao L, Liu Y, Yan G, Pu J.

Int J Biochem Cell Biol. 2008;40(10):2284-95. doi: 10.1016/j.biocel.2008.03.012. Epub 2008 Mar 25.

PMID:
18450499
18.

Antisense hypoxia-inducible factor 1alpha gene therapy enhances the therapeutic efficacy of doxorubicin to combat hepatocellular carcinoma.

Liu F, Wang P, Jiang X, Tan G, Qiao H, Jiang H, Krissansen GW, Sun X.

Cancer Sci. 2008 Oct;99(10):2055-61. doi: 10.1111/j.1349-7006.2008.00905.x.

19.

Beneficial effects of autologous bone marrow cell infusion and antioxidants/L-arginine in patients with chronic critical limb ischemia.

Napoli C, Farzati B, Sica V, Iannuzzi E, Coppola G, Silvestroni A, Balestrieri ML, Florio A, Matarazzo A.

Eur J Cardiovasc Prev Rehabil. 2008 Dec;15(6):709-18. doi: 10.1097/HJR.0b013e3283193a0f.

PMID:
19050436
20.

Increased endogenous angiogenic response and hypoxia-inducible factor-1alpha in human critical limb ischemia.

Ho TK, Rajkumar V, Ponticos M, Leoni P, Black DC, Abraham DJ, Baker DM.

J Vasc Surg. 2006 Jan;43(1):125-33.

Supplemental Content

Support Center